CureDuchenne Ventures is a Newport Beach, California based venture capital firm. They are the investment arm of CureDuchenne, a nonprofit dedicated to curing Duchenne muscular dystrophy. Their investments are focused on finding treatments and a cure for Duchenne muscular dystrophy.
CureDuchenne Ventures offers investment ranging from $50,000 to $5 million dependent on project needs. They also offer partnership and collaborations with the FDA, pharmaceutical and biotechnology industry. Their funding comes through in either grants, loans, or equity financing.
CureDuchenne Ventures has invested in Bamboo Therapeutics, Capricor Therapeutics, Collaborative Trajectory Analysis Project, Exonics Therapeutics, MyoTherix, Nationwide Children's, Biomarin, PTC Therapeutics, Sarepta Therapeutics, RASRx, TRiNDS, Baebies, 4DMT, Avidity Biosciences, ZappRx, and ReveraGen.
Edgewise Therapeutics is a drug discovery and biotechnology company developing products based on the understanding of skeletal muscle.
4D Molecular Therapeutics designs, develops and commercializes products for gene therapy.